Introduction
According to the generally accepted classification, esterases are enzymes which hydrolyse carboxylic acid esters of mono-and poly-hydric alcohols and phenols. Cholinesterases are distinguished from other esterases by a marked affinity for quaternary ammonium salts and complete inhibition in the presence of 10 /Lmol/I eserine (physostigmine). The structure of choline and of three of its esters particularly relevant to this bulletin appear in 
Historical background
In 1914, Sir Henry Dale suggested that a hydrolytic enzyme which destroys acetylcholine and choline esters was present in the blood. This suggestion was brought into prominence by the investigations of Loewi (1921) . Working with isolated frogs' hearts, Elsie Silk, J. King, and Mary Whittaker he showed that stimulation of the vagus causes the formation or liberation in the heart of a substance which itself produces the effect previously considered to be due to the action of the nerve. Loewi recognised that this so-called 'vagus substance' was a choline derivative. The physiological activities of the vagus substance and acetylcholine were found to be indistinguishable (Loewi and Navratil, 1921) . Moreover, both substances were inactivated by aqueous extracts of frog's heart; this destructive activity was removed by heating, indicating that it might be enzymic. Engelhardt and Loewi (1930) conclusively demonstrated the enzymic nature of the agent which destroys acetylcholine and considered it to be an esterase. It appeared logical to attribute the hydrolysis of acetylcholine by blood serum to the action of this enzyme which Stedman and Stedman (193 I) suggested was specific. The term 'cholinesterase' was proposed for the enzyme which hydrolyses esters of choline (Stedman et al., 1932) . ' Cholinesterase' thus assumed considerable importance in the transmission of the nerve impulse since it was recognised that this enzyme, by hydrolysing the acetylcholine released at the motor end-plate, permitted the nerve fibre to accommodate the next impulse.
Acetylcholinesterase (E.C.3.1.1.7) (acetylcholine acetylhydrolase) (International Union of Biochemistry, 1961 Biochemistry, , 1972 ) is now believed to be an integral part of the mechanism responsible for the development and propagation of the action potential at the motor end-plate. The electrical change and the production of acetylcholine are considered as two inseparable parts of one process.
In the years that followed the original findings of Stedman and his colleagues, an extensive literature appeared which was concerned with: (0) the enzymic hydrolysis of acetylcholine in the serum, erythrocytes, and other tissues of vertebrates and invertebrates; and (b) the specificity of cholinesterase and its relation to other esterases, especially those hydrolysing aliphatic esters. Early work centred on the cholinesterase of human and horse plasma. Since erythrocytes had long been known to have an acetylcholine-hydrolysing effect, the question arose whether the erythrocyte cholinesterase and the plasma cholinesterase were identical. Alles and Hawes (1940) concluded that the two enzymes were distinct. They demonstrated that the activity of the erythrocyte enzyme was greatest at low acetylcholine concentration and was inhibited by excess substrate; the activity of the plasma enzyme, on the other hand, increased with increasing substrate concentration and was not inhibited by an excess. Their studies were extended by several groups of workers, notably Mendel and his collaborators . Most crude cholinesterase preparations are capable of hydrolysing aliphatic esters. Mendel's group found that a relatively small degree of purification of the cholinesterase of the erythrocytes of several species deprived the cells of their ability to hydrolyse the typical aliphatic esters tributyrin and methyl butyrate. In other words, the erythrocyte enzyme seemed to be specific for acetylcholine esters. A much higher degree of purification of horse serum did not alter the rate of hydrolysis of the aliphatic esters relative to acetylcholine once it had fallen to a constant figure, whatever the further degree of purification. The serum enzyme, therefore, seemed more able tocatalyse the hydrolysis of the other choline esters than acetylcholine itself. The erythrocyte and serum types of cholinesterase were named 'true' and 'pseudo' cholinesterase respectively ; the 'pseudo' cholinesterase appeared to have no physiological function. Other nomenclatures were also proposed, none of them meeting with widespread approval. However, Mendel's conception of two main types of cholinesterase, one highly specific for acetylcholine and a few closely related esters, the other capable of hydrolysing both choline and aliphatic esters, has met with general acceptance. At the same time it was understood that this 'type theory' was not an exhaustive interpretation of the cholinesterase problem. It has been shown that cholinesterase is not a single entity with identical properties irrespective of the enzyme source. Indeed, Augustinsson (1948) regarded the cholinesterase as a 'family' of related enzymes with widely divergent properties. The activity differs in a given species from tissue to tissue, as well as in a given tissue from species to species.
Nomenclature
The generalisation of two main types of cholinesterase, one highly specific for acetylcholine and physiologically important, the other non-specific for acetylcholine and without known physiological function, now appears to be too narrowly conceived. Recent advances in our knowledge of the specificity Table 1 Cholinesterases 59 of the cholinesterases no longer justify this sharp distinction although it is a useful working classification. These more recent findings have made the allotment of correct nomenclature difficult. As indicated earlier, two enzymes have been designated as cholinesterases officially (Table 1) . Acetylcholinesterase is found in the nervous tissue of all animals and in the red cells of most of them. Cholinesterase is found in smaller amounts in the nervous system of all animals and in the blood plasma of most of them.
Possible physiological function of plasma cholinesterase
The physiological roles of cholinesterase and its natural substrates are matters for speculation. Perhaps the discovery that acetylcholinesterase and cholinesterase were different enzymes was misleading in that it led to the assumption that cholinesterase was not concerned with nervous transmission. However, in an important study on the brain and nerves of man and animals. Ord and Thompson (1952) demonstrated, by the interplay of specific substrates and inhibitors, that cholinesterase is present largely in the white matter of the central and peripheral nervous system in close association with the acetylcholinesterase of the grey substance. Hunt and Taveaux (1906) reported that a variety of choline esters had marked pharmacological effects in experimental animals. Propionyl, butyryl, valeryl, and aromatic esters of choline, as well as suxamethonium, altered the blood pressure and heart rate. It is now known that these esters inhibit true cholinesterase, and Bovet-Nitti and co-workers (Bovet et al., 1949) showed that they are hydrolysed by serum cholinesterase. Lehmann and Silk (1953) injected a series of different alkyl derivatives of choline into rabbit. They found that the alkyl groups closest to acetic acid (eg, propionyl and butyryl) produce the greatest increase in salivation and depolarising convulsions. Moreover, these substituted cholines are good substrates for pseudocholinesterase. Except for acetylcholine, the compounds tested have been synthesised in vitro, but undoubtedly similar substances must arise as intermediary metabolites in vivo. Any choline esters formed during metabolism will be present only in 60 small amounts and will be rapidly destroyed. However, Bannister et 01. (1951) have identified propionylcholine in an extract of ox spleen, while Nachmansohn et 01. (1949) found that an enzyme system derived from brain formed an unknown substance, not acetylcholine, with cholinergic properties. Accordingly, it has been plausibly suggested that the main physiological role of cholinesterase may be a protective one, that of hydrolysing those choline esters that may arise in vivo and which would inhibit acetylcholinesterase. This suggestion has received support from Clitherow et al. (1963) , who have indicated that butyrylcholine may be synthesised by the choline acetylase system from butyrylcoenzyme A during fatty acid metabolism and have argued that the function of cholinesterase may be to prevent accumulation of this substance. Further support has been provided by the demonstration of the presence of y-aminobutyryl choline in brain tissue (Holmstedt and Sjoquist, 1960) . Other studies have shown that cholinesterase affects intestinal motility (Jamieson, 1963) , and the enzyme may also play a part in transmittory processes in other tissues (Koelle, 1963) .
However, speculation concerning the role of cholinesterase must take into account that normal healthy individuals have been found who appear to be devoid of serum cholinesterase activity. This does not necessarily militate against the suggested function of the enzyme but points to the possible existence of alternative mechanisms in these subjects.
Cholinesterases of human blood
The acetylcholinesterase of human erythrocytes is bound to the cell membrane and is inhibited by an excess of acetylcholine. Acetylcholine is the only common naturally occurring substrate of acetylcholinesterase; however, it will also hydrolyse propionylcholine and acetyl-E-methylcholine (a specific substrate) and the thiocholine analogues of these three substrates. Using acetylcholine as substrate, serum cholinesterase has an optimal substrate concentration of about 2 x 10-2 M and is not inhibited by an excess. This enzyme not only catalyses the hydrolysis of acetylthiocholine but also propionyl-and butyrylthiocholine and their thion analogues. Butyrylcholine and butyrylthiocholine are specific substrates. Benzoylcholine is also a specific substrate, not being hydrolysed by the erythrocyte enzyme. The enzyme also catalyses the hydrolysis of a number of other esters of both choline and other alcohols.
Elsie Silk, J. King, and Mary Whittaker 
Mode of action of the cholinesterases
To explain the affinity of the cholinesterases for cationic substrates (Fig. I ) and inhibitors ( Fig. 2) , particularly those containing a positively charged nitrogen atom linked to methyl or ethyl groups, Zeller and Bissegger (1943) postulated combination of these compounds with the enzyme at two different sites at the active centre of the enzyme. The first of these, the 'anionic' site, is a negatively charged region of the enzyme surface, which combines with the positively charged quaternary nitrogen atom of the substrate or inhibitor. The second or esteratic site appears to combine with the carboxyl group of the ester linkage and to be responsible for the actual hydrolysis and for substrate specificity. This mechanism, while not entirely accepted by some workers who assert that serum cholinesterase possesses an esteratic site only, is represented dia- grammatically in Fig. 3 and would be compatible with the biochemical behaviour of the cholinesterase variants (see section 7.3).
MODE OF ACTION OF ACETYLCHOLIN-ESTERASE INHIBITORS
Inhibitors of acetylcholinesterase have been divided into two main groups, reversible and irreversible. Reversible inhibition is said to occur when the enzyme activity recovers after the inhibitor has been removed by dialysis or other means; in irreversible inhibition this does not normally occur. Some workers prefer to use the term 'organophosphorus' rather than 'irreversible' to describe this class of cholinesterase inhibitors. We do not recommend this.
Reversible inhibitors
Acetylcholine itself is a reversible inhibitor of acetylcholinesterase since excessive concentrations of this substance reduce enzyme activity. Two other widely used substances in this category are eserine (physostigmine) and neostigmine (prostigmine). Over 100 diverse compounds have been listed by Augustinsson (1948) as anticholinesterases, for example, procaine, cocaine, nicotine, morphine, codeine, colchicine, quinine, caffeine, urea, sulphonamides, chloroform, etc.
Irreversible inhibitors
These substances are all organophosphorus compounds, for example, di-isopropoxy-phosphoryl fluoride (DFP). They are used extensively as insecticides and have been used in gas warfare, for which purpose many of them were developed. A large number of these compounds are known, all possessing the same general structure: 7 Clinical significance 7.1 PATHOLOGICAL STATES While the site of synthesis of the enzyme found in the tissues is uncertain, there is abundant evidenoe that the cholinesterase found in relatively high concentration in the plasma (in contrast to other enzymes) is formed in the liver. Thus the concentration of cholinesterase appearing in the plasma at anyone time is a reflection of the rate of formation of the enzyme by the liver, thus providing an index of general synthetic capacity. Although the normal range is wide, the level of the enzyme is remarkably stable in anyone healthy subject. Determination of the enzyme may therefore be taken as a sensitive test of liver function. Table 2 shows the effect of the clinical state of the patient on the plasma level of the enzyme.
In the surgical treatment of the cirrhotic patient, assays of serum cholinesterase and albumin levels are the two most important estimations in assessing the prognosis of a patient before operation (portacaval or lienorenal anastomosis) and during the follow-up period (Hunt and Lehmann, 1960) . Serum cholinesterase assay has also proved helpful in assessing progress in cases of liver transplant (Evans and Lehmann, 1971 ).
ORGANOPHOSPHORUS POISONING
Both serum cholinesterase and red cell acetylcholinesterase are irreversibly inhibited bytheorganophosphates and carbamates, which are highly toxic. Organophosphates are widely used in industry, for example, in the manufacture of aeroplane 'dopes', and also as insecticides in agricultural and horticultural practice, for example, parathion and malathion. Ingestion of food contaminated with insecticides is the commonest cause of organophosphorus poisoning. In Japan, where insecticides are widely used to protect the rice crop, over 6000 cases occurred in five years (Namba and Hiraki, 1958) ; it is worth noting that the pilots of aircraft used in crop-spraying, of necessity carried out by low-level flight, are at considerable risk through inhalation of concentrated amounts of insecticides. The 'nerve' gases used in chemical warfare provided another example of the use of organophosphorus compounds which are also used more beneficially in medical therapeutics, for example, ecothiopate iodide, an organophosphorus compound, which is administered in the form of eye-drops in the modern treatment of glaucoma in order to reduce intraocular pressure. Such patients must be treated with caution since they may exhibit depressed levels of serum cholinesterase, indicating significant systemic absorption. Administration of the drug in pregnancy may also ultimately affect the serum cholinesterase level of the infant (Birks et al., 1968) . The characteristic effects of organophosphorus poisoning are a consequence of the specific inhibition of acetylcholinesterase at the neuromuscular junction. The systemic effect of acute poisoning becomes apparent within an hour or two and may last for several days, depending on the dose and the route of absorption by either the skin, respiratory tract, conjunctivae, or alimentary tract. The central nervous system, the muscles, and the gastrointestinal tract are all affected. Paralysis due to demyelination of the spinal cord may be delayed for several weeks, for example, in tri-o-cresyl phosphate poisoning. By contrast, death can occur within a few minutes after exposure to organophosphorus compounds due to paralysis of the respiratory muscles and depression of the respiratory centre. Chronic poisoning, in the generally accepted sense, does not occur, but continual absorption of subtoxic doses may occur in agricultural workers, finally culminating in the features of acute poisoning and even death.
Both erythrocyte acetylcholinesterase and serum cholinesterase may be estimated as indices of poisoning since their inhibition reflects the situation in the tissues. Continual exposure to subtoxic doses of organophosphates diminishes the activi ty of the two enzymes. When the exposure ceases, cholinesterase activity reverts to normal over a period of five to six weeks as the enzyme is resynthesised by the liver. However, it takes about four months for the acetylcholinesterase activity to return to normal as the red cells are replaced.
Assay of serum cholinesterase is preferred for screening and monitoring agricultural and industrial workers since it is capable of better definition, and its levels, in turn, reflect those of erythrocyte acetylcholinesterase.
7.3 SUXAMETHONIUM SENSITIVITY Serum cholinesterase is also assayed in patients who exhibit sensitivity to suxamethonium (succinyldicholine), which is marketed in the UK as Scoline. This is a widely used, short-acting muscle relaxant first introduced into clinical anaesthesia in 1951, facilitating such procedures as intubation, electric convulsive therapy, etc. Suxamethonium acts by effecting a chemical neuromuscular block (Feldberg, 1951) , causing excessive depolarisation, which spreads to the surrounding muscle fibres, making them unexcitable. It competes with acetylcholine for the cholinergic receptors at the neuromuscular junction, producing an acetylcholine-like but prolonged depolarisation of the end-plate.
Acetylcholine is rapidly hydrolysed by acetylcholinesterase. However, when suxamethoniurn is administered, it is not destroyed by acetylcholinesterase, and its action persists until it has been hydrolysed by serum cholinesterase. After initial contraction, the muscle fibres passively elongate to give the relaxation required by the anaesthetist. The duration of action is usually 3-5 minutes. Most of the body muscles, including the respiratory muscles, are relaxed during this period so that apnoea ensues, and it is necessary to maintain endotracheal ventilation until the patient breathes again spontaneously. In a small proportion of patients, the period of apnoea is prolonged and persists for hours. In these cases, artificial ventilation must be carried out until spontaneous respiration returns.
Many of the affected patients in the early cases reported were shown to have low serum cholinesterase levels, thought to result from impaired hepatic synthesis. A number of cases, however, were subsequently described in which liver disease could not be demonstrated (Bourne et al., 1952; Evans et al., 1952 Evans et al., , 1953 . Reconciliation of these facts remained unsolved until the work of Kalow and his colleagues (Kalow and Genest, 1957; Kalow and Staron, 1957; Kalow and Davies, 1958; Kalow, 1959) , who reported that the Michaelis-Menten curves for the hydrolysis of suxamethonium from the two types of patients demonstrated qualitative differences. The enzyme from the suxamethonium-sensitive patient appeared to be atypical in that it was not able to hydrolyse low concentrations of suxamethonium such as were found in the circulation after normal clinical dosage. By using dibucaine (a positively charged quaternary ammonium compound) as inhibitor at a concentration of 10-5 M, they showed a striking difference between the inhibition of the enzyme of normally responsive patients, about 80%, compared with the enzyme of sensitive patients, about 20 %, indicating an atypical enzyme which is now known as the 'dibucaine-resistant variant'. Kalow introduced the term 'dibucaine number', meaning the percentage inhibition of the enzyme in the presence of a fixed concentration of dibucaine under standard conditions. The differences described above were strong evidence that the serum cholinesterase found in persons sensitive to suxamethonium were a different molecular species from normal. Further evidence that the two cholinesterase variants are separate enzymes is provided by the fact that they can be separated by ion exchange chromatography or by electrophoresis at high pH (Liddell et al., I962a) . These techniques have also shown that both enzymes are present in the plasma of a heterozygote. The variant also appears in tissues other than plasma in an affected individual (Liddell et al., 1963) .
Another positively charged inhibitor, which has 63 been used by Liddell et al. (1963) to segregate the two variants, is the dimethyl carbamate of (2-hydroxy-5-phenylbenzyl) trimethyl ammonium bromide (Hoffman La Roche RO 2-0683).
Pharmacogenetics ofsuxamethanium
It had already been suggested that there could be an hereditary basis for the low serum cholinesterase levels where hepatic function appeared normal (Forbat et al., 1953; Lehmann and Ryan, 1956; Lehmann et al., 1958) . The use of dibucaine now became the means of confirming this hypothesis. The heterozygotes, presumably possessing a mixture of both enzymes, were usually found to have intermediate levels of activity. However, in certain families, it was observed that one of the parents or children of an 'atypical' individual appeared to have only the 'usual' type enzyme (Kalow and Staron, 1957; Harris et al., 1960; Liddell et al., 1962b) . A possible explanation for these findings was offered by Kalow and Staron (1957) . They suggested that there were a number of allelic genes for the 'usual' serum cholinesterase, each determining its production at a different rate. The extreme of such a series would be an allele producing an absence of serum cholinesterase activity. If such a gene occurred, then one would expect that heterozygotes of this gene and the 'atypical' gene would form only the 'atypical' enzyme, whereas the heterozygotes of this gene and the 'usual' gene would form only the 'usual' enzyme. The homozygotes would, of course, display a complete or nearly complete absence of serum cholinesterase activity. Liddell et al. (1962b) also described a suxamethonium-sensitive individual in whom serum cholinesterase activity was immeasurable; it was suggested that this patient was homozygous for the 'silent' gene. A number of other individuals with this rare condition have been identified (Doenicke et al., 1963; Goedde et at., 1965; Hodgkin et al., 1965) . Whether the postulate of Kalow and Staron (1957) is entirely correct in its implications is a matter of some conjecture.
Other important differential inhibition studies of cholinesterase activity were performed by Harris and Whittaker (1961) . They demonstrated that it was not essential for a differential inhibitor to be positively charged, by showing that sodium fluoride provided a similar inhibition segregation to that of dibucaine. In addition, a population was identified by differing inhibitions to dibucaine and fluoride (Harris and Whittaker, 1962 ).
The four variants described above are believed to be alleles of the same gene functioning at the locus E1 . More recently, other inhibitors, such as chloride Whittaker, 1968a) , 64 alcohol (Whittaker, 1968b) , and scoline (McComb et al., 1965) , have been described.
When serum cholinesterase is examined electrophoretically, four bands of isozymes are regularly observed. The C4 band is the slowest moving and contributes about 90% of the total serum cholinesterase activity. However, an extra isozyme, C5, is seen in about 10 % ofCaucasian populations; these individuals are not suxamethonium-sensitive. The biosynthesis of C5 appears to be controlled by a gene situated at a separate locus, E2 , and genetically independent of the cholinesterases situated at the locus EI. Sera from C5 + individuals (ie, those with the extra isozyme) have a mean cholinesterase activity about 30% higher than sera from those without it.
Cholinesterase-variant nomenclature
Two conventions have been proposed for classifying the generally recognised genes. In the first nomenclature (Motulsky, 1964) , the two loci are designated EI and E2, while the second nomenclature of Goedde and Baitsch (1964) uses ChI and Ch 2. The four variants at the first locus are symbolised Ei U or Chi U for the usual enzyme, Ela or Ch III for the atypical (dibucaine-resistant) gene, Ei [ or Ch 1F for the fluoride-resistant allele, and E 1 S or Ch IS for the silent gene. At the second locus, the variants are designated E2-or Ch2-for normals, or E2 j or Ch2+ for the C5 variants. In this review the Motulsky convention will be used exclusively.
Investigation 0/suxamethonium apnoea
Prolonged apnoea after suxamethonium is not a common occurrence. Unfortunately, there have been few surveys of the frequency of this situation. However, Bauld et al. (1974) reported, on the basis of reasonably accurate figures obtained at the Edinburgh Royal Infirmary over a period of two and a half years, an incidence of I in 1800 administrations. The data demonstrated that apnoea was not always confined to patients possessing a serum cholinesterase variant but occurred in patients with Elsie Silk, J. King, and Mary Whittaker any genotype. This part of the study confirmed the findings in other surveys (Kalow, 1965; Thompson and Whittaker, 1966; Liddell, 1969: Whittaker and Vickers, 1970) , as shown in Table 3 .
The Edinburgh study also showed that, among patients with a normal activity of the usual enzyme (34 %), it was likely that neuromuscular block was not present in all cases. In some patients this was actually demonstrated by use of a peripheral nerve stimulator, a relatively inexpensive instrument. In others, the conclusion was made, in the absence of availability of a peripheral nerve stimulator, on the basis of easily reversed hyperventilation, response to carbon dioxide challenge or movement of the endotracheal tube, the absence of postoperative muscle weakness, and a normal response to a later administration of suxamethonium. Inappropriately large doses of suxarnethoniurn, sedative premedication, and tacrine were implicated as causes of prolonged apnoea in four patients.
A further possible cause of prolonged apnoea has been suggested, namely, that cholinesterase variants exist that are not detectable by present methods. Such variants undoubtedly exist and in large numbers (Bauld et al., 1974) . On this basis, it was postulated that some of these variants were likely to have reduced catalytic activity, would be unable to hydrolyse suxamethonium, and would thus give rise to suxamethonium hypersensitivity. They further suggested the feasibility of such variants being able to bind and hydrolyse the chemically different substrates now used while escaping detection by present assay methods. Obviously these variants do not bind and hydrolyse suxamethonium, and therefore it is possible that they might be discovered by using suxamethonium as the substrate for assay. However, the hydrolysis of low concentrations of suxamethonium such as those existing in plasma after administration (less than 5 x 10-5 Mil) is far from easy to measure.
The importance of a complete study of patients with prolonged apnoea after suxamethonium has been emphasised (British Journal of Anaesthesia, grounds for the prolonged apnoea, wider family studies should be undertaken to try to identify other members of the family who may be 'at risk'. It would be advisable to carry out these studies in conjunction with the regional/ national laboratories which would act as reference centres so that information may be colIated and extended. These centres wiII also be able to assist with any difficulties encountered with phenotyping for serum cholinesterase. (e) Warning cards should be issued to alI patients and relatives with cholinesterase genotypes invariably associated with suxamethonium sensitivity. The card should give the name and address of the issuing centre/laboratory to whom reference may be made. Alternatively, the patient and relatives may be registered with Medic-Alert. (f) The problem should be explained to the cardholder, and the importance should be stressed of carrying the card at alI times and showing it to medical staff on any admission to hospital or dental surgery. At the same time reassurance should be given that the card-holder is not suffering from any organic complaint. (g) The patient's case records must be clearly marked.
(h) The correct policy for heterozygotes, that is, those possessing one gene for the usual form of cholinesterase, is difficult. In general, heterozygotes should be given warning cards when the enzymic activity is less than 50% of the average found for the usual homozygote. These patients should be reinvestigated several weeks after recognition to ensure that serum cholinesterase activity has not risen and to confirm the variant situation.
8 Principal assay procedures 8.1 SERUM CHOLINESTERASE (E.c.3.1.1.8)
Numerous procedures are available for the estimation of serum cholinesterase (Augustinsson, 1971 )-fixed time, fixed end-point, and initial rate reaction methods. In general, these assays may be divided into three categories. First, there are those measuring the liberation of acid, from a choline ester, by (a) estimating the carbon dioxide released from a bicarbonate-containing medium in the Warburg manometric apparatus (Ammon, 1933; McArdle, 1940) , a very sensitive and accurate assay, (b) the time taken to achieve a fixed pH electrornetrically (Michel, 1949; CourvilIe and Ledington, 1951) or colorimetricalIy by means of indicators such as phenol red (Reinhold et al., 1953; Molander et al., 1954; Caraway, 1956 ), bromthymol blue (Biggs et al., 1958) , or m-nitrophenol (Rappaport et al., 1959) , and (c) measuring the rate of manual (Stedman et al., 1932; Glick, 1938; Alles and Hawes, 1940) or automatic (Jorgensen, 1959; Nabb and Whitfield, 1967) , continuous titration to maintain a constant pH.
In the second group, use is made of chromogenic substrates, such as ,B-carbonaphthoxycholine, coupling the liberated ,B-naphthol with tetrazotised dithioanisidine (Ravin et al., 1951) or non-choline esters such as phenyl benzoate with which the phenol liberated by enzymic hydrolysis is estimated with the Folin-Ciocalteau reagent (Smith et al., 1959) . Reaction rate procedures with substrates of doubtful specificity for cholinesterase, such as indophenylacetate at 625 nm (Kramer and Ganeson, 1958) or o-nitrophenylbutyrate at 414 nm (Main et al., 1961; McComb et al., 1965; Szasz, 1968a; Whittaker and Hardisty, 1969) , have also been published. Perhaps the most generally successful approach has been that using thiocholine esters and the estimation of the sulphhydryl group released by enzymic hydrolysis. This has been followed by means of the nitroprusside colour reaction (McOsker and Daniel, 1959) or by iodometric titration (Augustinsson, 1955a) , in two-point assays or in reaction rate procedures by coupling to the reduction of 2:6 dichlorophenolindophenol, reading at 600 nm (Gal and Roth, 1957) , by complexing with 2,2' or 4, 4'-dithiodipyridine and reading at 324 or 343 nm respectively (Uete et al., 1972) , or with 5,5'-dithiobis-(2-nitrobenzoic acid) following the reaction at 410 nm (Ellman et al., 1961; Garry and Routh, 1965; Szasz, 1968a and b; Garry, 1971) . The last is a simple and sensitive procedure.
In the final group, the unreacted ester is estimated. This has been done in fixed-time assays using an acetylcholine substrate by means of the ferrichydroxamate reaction (De La Huerga et al., 1952) , or in reaction rate procedures with thiocholine substrates using absorption of the ester at 226 nm or with benzoylcholine by following the change in absorption at 240 nm (Kalow and Lindsay, 1955) . The last method is of particular interest because of the recognised specificity of the substrate and the fact that it is an initial reaction rate assay which has excellent precision. The genetic variants were defined in terms of inhibition of benzoylcholine hydrolysis (see sections 9.1 and 9.3).
ACETYLCHOLINESTERASE (E.c.3.l.l. 7)
Many of the procedures discussed in section 8.1 may be applied to the assay of acetylcholinesterase, provided that the appropriate substrate is used, for example, acetylcholine, acetyl-,B-methylcholine, and acetylthiocholine.
9 Choice of assay procedures for the service laboratory 9.1 SERUM CHOLINESTERASE (E.c.3.1.1.8) Recommended methods for serum cholinesterase assay will be published shortly as part of a series of Association of Clinical Biochemists recommended methods. The considerations discussed in this section were borne in mind when formulating the recommended procedures.
Several points arise in considering a suitable method for the routine assay ofserum cholinesterase:
(a) There is some controversy concerning the influence of ions on the activity of the enzyme but K +, Na+, Mg r t, and Ca ++ are considered to be activators (Augustinsson 1948 (Augustinsson , 1955b Mendel and Rudney, 1945 ). There appears to be sufficient native Mg++ or Car t present in the serum, but if the addition of these ions to the reaction mixture is omitted, then anticoagulants such as oxalate or citrate, which combine with these ions, must not be used when obtaining the blood sample.
(b) Kinetic procedures are preferable to twopoint assays.
(e) Stringent control of the reaction temperature is necessary to obtain accurate results. It should be (d) It is better to employ a procedure where application of heat is necessary to bring the assay conditions to the required temperature, thereby ensuring that changes of temperature of the solutions during mixing are kept at a minimum. Where ambient temperatures are above the desired assay temperature, it may be necessary to modify existing apparatus (King and Ritchie, 1973) for phenotyping purposes.
(e) For the last 20 years, the isoenzyrnes which form the serum cholinesterase variants have been defined by their inhibitions under specific assay conditions, and attempts to distinguish them by alternative processes have not been notably successful to date. The methods used to distinguish the variants cannot be said to be really appropriate for routine service purposes since they require not only considerable experience and expertise, especially in interpretation of results, but also apparatus which may not readily be available in a number of laboratories. It therefore seems desirable to use two assay procedures, one for serum cholinesterase activity in conditions other than suxamethonium sensitivity and one for the latter situation.
PROCEDURE FOR DETERMINATION OF SERUM CHOLINESTERASE ACTIVITY IN CONDITIONS OTHER THAN SUXAMETHONIUM

SENSITIVITY
Because of their relative simplicity and sensitivity, assays which follow the hydrolysis of thiocholine esters are preferred. These involve the reaction (Ellman, 1959) with 5,5' -dithiobis-(2-nitrobenzoic acid) in which the liberation of the yellow 5-thio-2-nitrobenzoic acid (Fig. 4) has been used by a number of workers to follow the enzymic hydrolysis at wavelengths varying from 405 to 420 nm, although Ellman carried out his observations at 412 nm, Garry and Routh (1965) were the first to use this principle, one of the most straightforward developed, for the assay of human serum cholinesterase, and the kinetics of the reaction have been well investigated. The method is based upon the measurement of reaction product instead of the remaining intact substrate and has a number of advantages. These are simplicity, high precision, pH constancy, flexibility, short incubation periods, and continuous increase in colour density as a function of incubation time. Another advantage lies in the method being dependent on changes in the visible region of the spectrum. This is convenient when checking unusual changes in butyrylthiocholine at 37°C (see section 9.2.1 (c) .. However, there is considerable non-enzymatic hydrolysis in these conditions, which would give rise to high reagent blank readings in an assay procedure. When the substrate concentration is reduced to 3 mMat 37°C, the spontaneous hydrolysis is negligible and can be ignored for working purposes. While enzyme activity is not optimal at this concentration of butyrylthiocholine, a linear relationship between the rate of disappearance of substrate with time and enzyme concentration is still obtained. the absorbance, for example, turbidity, spills on the photocellwindow, etc.
Choice ofreaction conditions
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In expressing preference for a procedure based on the use of a thiocholine ester, we have borne in mind that solutions of these compounds are not very stable and that non-enzymic hydrolysis cannot be ignored. Experimental studies by King (1974) showed that spontaneous hydrolysis increased in the order butyryl-, propionyl-, acetyl-, succinyl-at any given temperature (Fig. 5) , and while the percentage rate of hydrolysis remained virtually constant, the absolute amount of product increased with substrate concentration. Since butyrylthiocholineis the least labile of the thiocholine esters and because it is relatively specific for the enzyme, this is the substrate of choice for routine purposes. Maximum activity of the enzyme is obtained at pH 8,5-9,0 using 10 mM concentrations of the King (1974) demonstrated that there was an increase in enzyme activity and an apparent increase in spontaneous hydrolysis of substrate with increasing pH (Fig. 6) . He inferred that the increase in the latter was due in part to the increased absorption of the indicator ion with pH (Fig. 7) , which would account for the observed variation in enzyme activity with hydrogen ion concentration. Therefore despite a pH optimum of 8'5, the use of 67 roM Sorensen's phosphate buffer, pH 7,4, is preferred. This reduces the undesirable non-enzymic hydrolysis to negligible proportions and still allows the linear relationships of the assay procedures to obtain at 37°C. A major factor underlying this preference was the alignment with assay procedures for the determination of suxamethonium activity. Phospho'p (c) Choice of temperature (also see section 9.3.1 (c» A true index of serum cholinesterase activity can be obtained only if the estimation is conducted at 37°C. Lehmann et al. (1958 Lehmann et al. ( , 1960 emphasised this fact by effecting a better separation of the phenotypes when assaying total activity at this temperature (see sections 7.3 and 7.3.1). Further reinforcement of their work has been provided by the studies of King and Griffin (1974) . They assayed the activity of a number of specimens of various phenotypes at 25°C and 37°C using benzoylcholine as substrate. A wide overlap of activities from all phenotypes occurred at 25°C (Fig. 8) , a number of suxametho- nium-sensitive individuals having serum cholinesterase activities which could only be classed as normal. The activities determined at 37°C did not alter the distribution of the usual homozygotes significantly, but a larger proportion of the usual/ atypical heterozygote group displayed activities which fell below the lower limit of normal. There was a conclusive change, however, in the distribution of the three suxamethonium-sensitive phenotypes where all the activities were found to be abnormally low (Fig. 9) . Comparable studies of the temperature-activity of serum cholinesterase phenotypes were undertaken using several thiocholine substrates with similar results (King and Ritchie, 1973) . For these reasons, the adoption of 37°C as the standard temperature for the routine assay of serum cholinesterase activity in conditions other than suxamethonium activity is preferred.
(b) Choice ofbuffer and pH
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PROCEDURE IN CASES OF SUXAMETHO-NIUM SENSITIVITY
Choice ofreaction conditions (a) Choice ofsubstrate
In the above situation, benzoylcholine is the substrate of choice since it possesses a number of advantages for studies on serum cholinesterase. It is specific for the enzyme and therefore can accommo-69 date a degree of haemolysis in the test serum without affecting the results. Benzoylcholine has a much greater absorption at 235 om than its hydrolysis products (Kalow, 1952) . Thus the rate of hydrolysis can be monitored readily in an ultraviolet spectrophotometer. Benzoylcholine also provides the facility of an initial reaction rate assay. The validity of such assays compared with other types of enzyme activity has been well established. In addition, the simplicity of the method has made it suitable for kinetic and other studies.
Our preference is governed partially by historical considerations. Benzoylcholine has proved to be a particularly useful substrate in the study of the allelic variants of human cholinesterase. It was used by Kalow and his colleagues as a means of identifying the dibucaine-resistant variant, and by Harris and Whittaker (1962) in the identification of the fluoride-resistant variant. Kalow and Lindsay (1955) did not follow the substrate hydrolysis at 235 nm but at 240 nm. This minimised the optical effect of the serum and was an important consideration since the then available spectrophotometers had limited performance. The difference in absorption between benzoylcholine and its hydrolysis products was found to be greatest at 235 nm and less than 10% lower at 240 nm. However, at 235 nm the dilute (1 :200) serum itself increased the absorption by 1·2 units; at 240 nm this increase was only 0·5. The latter wavelength was obviously 1 ' 0 the observed anomalies of another factor, namely, the inactivation at body temperature of the enzyme variants present in the serum of suxamethoniumsensitive subjects which reduces the rate of hydrolysis. They studied the temperature-activity relationships of the variants, using benzoylcholine as substrate, and expressed the results relative to unity at 25°C. It was demonstrated that there was a characteristic temperature-activity curve for each phenotype and, for those phenotypes most sensitive to suxamethonium, the curve differed radically from that of the normal enzyme (Fig. 10) . The temperature activity 2.
chosen because it gave an acceptable initial absorption while retaining adequate sensitivity in following the hydrolysis of the substrate. Since the comparatively small difference in wavelength is so significant, it is important to use a properly calibrated spectrophotometer of good resolving power. Kalow and his co-workers used a 50 fLM concentration of benzoylcholine in the final reaction mixture, at pH 7'4, given by a 0·067 M Sorensen phosphate buffer. Such conditions did not give maximal activities but, as with the choice of wavelength, they were optimal compromises. Later studies by these workers showed that they were obviously aware of the suboptimal conditions of their assay system. They reported a ratio of 5·5 between the Michaelis-Menten constants for the atypical and usual enzymes and of 0·5 for the Ymax ratio (Davies et al., 1960) , thereby indicating that the substrate concentration for maximal activity varied with the cholinesterase phenotype.
(b) Choice ofbuffer and pH
Phosphate was chosen as a buffer by Kalow (1952) because of its low extinction coefficient in the ultraviolet. The optimum pH varies with the type and ionic strength of the buffer, with the substrate concentration, and also with the enzyme variant (Kalow, 1964) . The usual enzyme has an optimum pH about 9'0, the atypical about 8·5 when a concentration of 50 fLM benzoylchoJine and 0·067 M Sorensen phosphate buffer is used in the assay system. At a 100 fLM substrate concentration, the atypical pH optimum was found to increase slightly towards that of the usual enzyme at its optimal substrate concentration (King, 1974) . However, the spontaneous hydrolysis of the substrate was no longer negligible at these hydrogen ion concentrations and certainly not at higher temperatures. It was this factor that had determined the original choice of pH 7'4, which is still preferred.
(c) Choice oftemperature (also see section 9.3.1 (e) Not all prolonged responses to suxamethonium can be attributed to enzymic anomalies, and indeed they may not be attributable to suxamethonium alone but may be caused by a complex situation dependent upon a number offactors (see section 7.3.3). Table 3 summarises the findings in five separate surveys, all showing that over 50 % of patients suffering from suxamethonium apnoea were usual homozygotes or heterozygotes. Where apnoea is connected with an inherited cholinesterase variant, it has been assumed that the sole cause is the reduced affinity for suxamethonium. However, the work of King and his collaborators (King and Dixon, 1969; King and Morgan, 1970) showed the important contribution to curves for EIUEl" and EluElu were identical. A subsequent study (King et al., 1971) reported that phenotype ElfElf also had its own characteristic temperature activity curve. With such differences between the variants, it was suggested that assays be carried out at a standard temperature, preferably 37°C, for valid results. The use of 37°C would permit a better separation of the phenotypes. This reasoning received support from the work of Lehmann and his associates (Lehmann et al., 1958; Harris et al., 1960) (see sections 7.3 and 7.3.1), who conducted their estimations at 37"C and found a better correlation between cholinesterase activity and suxamethonium activity than others who used a lower reaction temperature (Bush, 1961) .
Further work by King and Griffin (1974) demonstrated two reasons for the absence of correlation between enzymic parameters and apnoeic response. Firstly, they found a wide overlap of activities from all phenotypes at 2S oC (Fig. 8) . On raising the temperature to 37°C, they found that the distribution of activities of the usual enzyme was relatively unchanged. However, the activity of the three suxamethonium-sensitive phenotypes was markedly reduced, and all these activities became abnormally low (Fig. 9) . These findings corroborated the earlier work and underlined the suggestion that a valid assay of cholinesterase activity could be obtained only at 37°C.
Secondly, it was shown that a lack of correlation occurred with the fluoride-resistant homozygote El'El', the dibucaine number of which is of the same order as the non-sensitive EiuEl'" heterozygote at 2S oC. Again, the explanation lay with the assay temperature used. that the change in dibucaine inhibition with temperature is more pronounced with the EllEl f phenotype than with the others. At 37"C the dibucaine number is similar to that of the sensitive El"'Elf phenotype. In view of these facts, it would undoubtedly seem desirable to conduct the biochemical investigation at 37°C. The exception to this is illustrated in Fig. 12 , where it can be seen that the fluoride inhibition is acutely temperaturedependent and that it is not possible to retain the phenotype discrimination at 37°C. Two inhibitor numbers, one of which must be fluoride, are required to provide a precise phenotype identification, and this must be determined at the lower temperature of 2S oC, hence the continued use of 2S oC in serum cholinesterase/variant assay. However, an understanding of the two effects of temperature considered above will permit a better correlation between the biochemical specifications and the anaesthetic realities.
(d) Fluoride inhibition
Fluoride number determinations may be carried out by the routine service laboratory but stringent temperature control and reagent handling are required. A considerable degree of experience is required in the interpretation of results. It is therefore suggested that where enzyme activity and dibucaine numbers are of such value as to indicate further investigation, it might be advisable to consult a reference laboratory.
An interesting observation concerning the fluorideresistant gene was reported by King et aL. (1971) . Anomalies occurred in term pregnancy in individuals possessing this gene, and a change in inhibitor numbers was reported. The change was paralleled by alterations in the temperature-activity relationships. This constitutes the first recording of a cholinesterase mutation outside the control of the structural gene and is further proof that there is a structural difference between this variant and the others. Recently, Whittaker et al. (1977) and Ellis et al, (1978) have reported an increased incidence of the fluoride-resistant gene in patients susceptible to malignant hyperpyrexia after the administration of certain anaesthetics, for example, halothane and suxamethonium. To date, no firm explanation of this phenomenon has been advanced.
(e) Silent gene
The homozygote EISEl" is identified by a virtual absence of detectable enzyme activity. The heterozygote, on the other hand, can usually be assigned only after detailed family studies.
(f) Discussion
Neither the monitoring wavelength nor the reaction pH were maximal in the original assay of Kalow and Lindsay (1955) but were optimal compromises. However, it would be difficult to suggest alternative conditions that could be considered as being superior. Even if this were possible, the knowledge with regard to phenotyping accumulated over the intervening years would become invalid and nothing would be gained by repeating the exercise with new assay conditions. Accordingly, we prefer the adoption of the procedures of Kalow and Lindsay (1955) , which give remarkably reproducible results.
10 Acetylcholinesterase (E.C. 3.1.1.7) Overall, the considerations discussed under section 8.1 can be applied to the choice of an assay procedure for red cell acetylcholinesterase. Ellman's method, based on the use of the specific substrate acetylthiocholine, would undoubtedly be suitable chemically. However, this procedure (or indeed any other) cannot be readily utilised without prior consideration of the problem of the mode of lysis of the erythrocytes. Since the enzyme is membrane-bound, the activity obtained is dependent upon the method used in producing the enzyme solution. At present there is no known standardised procedure for this. A number of important considerations are involved in standardisation, all hinging on the method of preparation of the sample before enzyme estimation. These involve the choice of: (a) anticoagulant and its ratio to the amount of blood sample collected in relation to possible inhibition of the enzyme; (b) suitable units in which to express the assay results, for example, haemoglobin, erythrocyte count, etc. The latter would be a major factor Elsie Silk, J. King, and Mary Whittaker in determining the method oflysis and ultimate calculation of results; (c) the lysing agent and its possible enzymic inhibitory effects; (d) the treatment of the 'ghosts' in relation to background absorbance. Even if standardisation could be achieved, the final assay procedure would probably render the method burdensome and therefore unsuitable for the accurate estimation of acetylcholinesterase by the service laboratory. A crude estimate could be made but the assistance of a reference laboratory should be sought for a more precise determination.
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